Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00335283 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Lansoprazole in Chronic Post Nasal Drip
A Phase 3 study of Larynx Disease, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 3
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT00335283 is a Phase 3 study of Larynx Disease that has completed, run by Vanderbilt University. The registered enrollment target is 75 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00335283, a Phase 3 study of Larynx Disease, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether aggressive acid suppression with Lansoprazole is effective in the treatment of post nasal drip, and also assess the predictors of response based on clinical and physiologic parameters.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Lansoprazole Tablet
- PROCEDURE PH and impedence testing
- PROCEDURE manometry
- DRUG lansoprazole
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center, Vanderbilt Digestive Disease Clinic, TVC, Room 1660 - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00335283
The ClinicalTrials.gov registry entry for NCT00335283 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Larynx Disease appearing as the primary indexed condition, and to 5 interventions - of which placebo is the first listed.
NCT00335283 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT00335283 about?
NCT00335283 is a clinical study titled "Efficacy of Lansoprazole in Chronic Post Nasal Drip". The purpose of this study is to determine whether aggressive acid suppression with Lansoprazole is effective in the treatment of post nasal drip, and also assess the predictors of response based on clinical and physiologic parameters.
What is the current status of trial NCT00335283?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 75 participants. The study started on 2006-08. Estimated completion is 2008-12.
What conditions does trial NCT00335283 study?
This clinical trial studies the following conditions: Larynx Disease.
What interventions are being tested in trial NCT00335283?
The interventions under investigation include: placebo (DRUG), Lansoprazole Tablet (DRUG), PH and impedence testing (PROCEDURE), manometry (PROCEDURE), lansoprazole (DRUG).
Who is sponsoring clinical trial NCT00335283?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00335283 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Larynx Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.